Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?
Fiche publication
Date publication
janvier 2008
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha, Dr GUERIN Eric
Tous les auteurs :
Entz-Werle N, Velasco V, Neuville A, Geoerger B, Mathieu MC, Guerin E, Kehrli P, Gaub MP, Vassal G, Grill J
Lien Pubmed
Résumé
Several publications have recently focused on the erbB2 receptor in pediatric medulloblastomas (MBs) and its prognostic consequence. We determined erbB2 expression in 23 MBs at diagnosis. After DNA extraction, quantitative PCR targeting the erbB2 gene was performed and correlated with FISH analysis and immunohistochemistry. The samples were representative of the spectrum of the disease apart from the absence of large cell MBs. Using the tools validated for breast cancers by the FDA, we did not observe any expression or amplification of erbB2 and hence we speculate that MBs are not a good target for treatment with anti-erbB2 antibodies.
Référence
Pediatr Blood Cancer. 2008 Jan;50(1):163-6.